These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. Linton A; Soeberg M; Broome R; Kao S; van Zandwijk N Respirology; 2017 Jul; 22(5):978-985. PubMed ID: 28139858 [TBL] [Abstract][Full Text] [Related]
44. [Possibilities of diagnosis and treatment of malignant pleural mesothelioma]. Cicenas S; Zaremba S; Jakubauskiene R Medicina (Kaunas); 2004; 40 Suppl 1():152-5. PubMed ID: 15079127 [TBL] [Abstract][Full Text] [Related]
45. Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma? Mlika M; Ayadi-Kaddour A; Ksantini M; Bouraoui S; Mzabi S; El Mezni F J Immunoassay Immunochem; 2013; 34(2):111-25. PubMed ID: 23537297 [TBL] [Abstract][Full Text] [Related]
47. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases. Barbieri PG; Consonni D; Schneider M Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756 [TBL] [Abstract][Full Text] [Related]
51. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology. Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183 [TBL] [Abstract][Full Text] [Related]
52. Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma. Nakajima Y; Kuribayashi K; Ishigaki H; Tada A; Negi Y; Minami T; Takahashi R; Doi H; Kitajima K; Yokoi T; Kijima T Cancer Invest; 2020 Jul; 38(6):356-364. PubMed ID: 32468861 [TBL] [Abstract][Full Text] [Related]
53. [Mesothelioma of the pleura in the Province of Trieste]. Bianchi C; Bianchi T; Tommasi M Med Lav; 2007; 98(5):374-80. PubMed ID: 17907531 [TBL] [Abstract][Full Text] [Related]
54. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143 [TBL] [Abstract][Full Text] [Related]
56. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach. Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167 [TBL] [Abstract][Full Text] [Related]
57. The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma. Nakas A; Waller D; Lau K; Richards C; Muller S Eur J Cardiothorac Surg; 2012 Jul; 42(1):72-6; discussion 76. PubMed ID: 22290929 [TBL] [Abstract][Full Text] [Related]
58. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component. Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615 [TBL] [Abstract][Full Text] [Related]